Metabolic syndrome in youth: Current insights and novel serum biomarkers

Biomarkers in Medicine

Volumn 6, Issue 6, 2012, Pages 719-727

  Santoro, Nicola ^a   Weiss, Ram ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

adiponectin; FDF21; insulin resistance; metabolic syndrome; PEDF; pigment epithelium derived factor; RBP4

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 21; GLUCOSE TRANSPORTER 4; INSULIN; PIGMENT EPITHELIUM DERIVED FACTOR; REACTIVE OXYGEN METABOLITE; RETINOL BINDING PROTEIN 4;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; CARDIOVASCULAR RISK; CHILDHOOD OBESITY; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME REGULATION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID METABOLISM; LIPID PEROXIDATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PREVALENCE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHILD; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 84870915680     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.85     Document Type: Review

References (99)

1. Reaven GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Ann. Rev. Med. 44, 121-131 (1993
2. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350(23), 2362-2374 (2004
3. Reinehr T, Wunsch R, De Sousa G, Toschke AM. Relationship between metabolic syndrome definitions for children and adolescents and intima-media thickness. Atherosclerosis 199(1), 193-200 (2008
4. Zimmet P, Alberti G, Kaufman F et al. The metabolic syndrome in children and adolescents. Lancet 369(9579), 2059-2061 (2007
5. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 75(3), 473-486 (1995
6. Weiss R, Taksali SE, Dufour S et al. The 'obese insulin-sensitive' adolescent. importance of adiponectin and lipid partitioning. J. Clin. Endocrinol. Metab. 90(6), 3731-3737 (2005
7. Weiss R. Fat distribution and storage: How much, where, and how? Eur. J. Endocrinol. 157(SUPPL1), S39-S45 (2007
8. Taksali SE, Caprio S, Dziura J et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent. A determinant of an adverse metabolic phenotype. Diabetes 57(2), 367-371 (2008
9. Koutsari C, Jensen MD. Thematic review series: Patient-oriented research. Free fatty acid metabolism in human obesity. J. Lipid Res. 47(8), 1643-1650 (2006
10. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96(9), 939-949 (2005
11. D'Adamo E, Santoro N, Caprio S. Metabolic syndrome in pediatrics: Old concepts revised, new concepts discussed. Pediatr. Clin. North Am. 58(5), 1241-1255, (2011
12. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40(6), 1387-1395 (2004
13. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 58(11), 1538-1544 (2009
14. Burgert TS, Taksali SE, Dziura J et al. Alanine aminotransferase levels and fatty liver in childhood obesity: Associations with insulin resistance, adiponectin, and visceral fat. J. Clin. Endocrinol. Metab. 91(11), 4287-4294 (2006
15. Cali AM, De Oliveira AM, Kim H et al. Glucose dysregulation and hepatic steatosis in obese adolescents: Is there a link? Hepatology 49(6), 1896-1903 (2009
16. D'Adamo E, Northrup V, Weiss R et al. Ethnic differences in lipoprotein subclasses in obese adolescents: Importance of liver and intraabdominal fat accretion. Am. J. Clin. Nutr. 92(3), 500-508 (2010
17. D'Adamo E, Cali AM, Weiss R et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 33(8), 1817-1822 (2010
18. Weiss R, Dufour S, Taksali SE et al. Prediabetes in obese youth. A syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362(9388), 951-957 (2003
19. Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell 148(5), 852-871 (2012
20. Samuel VT, Petersen KF, Shulman GI. Lipid-Induced insulin resistance: Unravelling the mechanism. Lancet 375(9733), 2267-2277 (2010
21. Dube JJ, Amati F, Stefanovic-Racic M, Toledo FG, Sauers SE, Goodpaster BH. Exerciseinduced alterations in intramyocellular lipids and insulin resistance: The athlete's paradox revisited. Am. J. Physiol. Endocrinol. Metab. 294(5), E882-E888 (2008
22. Bergman BC, Hunerdosse DM, Kerege A, Playdon MC, Perreault L. Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans. Diabetologia 55(4), 1140-1150 (2012
23. Civitarese AE, Ravussin E. Mitochondrial energetics and insulin resistance. Endocrinology 149(3), 950-954 (2008
24. Subasinghe W, Syed I, Kowluru A. Phagocyte-like NADPH oxidase promotes cytokine-Induced mitochondrial dysfunction in pancreatic beta-cells: Evidence for regulation by Rac1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300(1), R12-R20 (2011
25. Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 129(3), 557-570 (2012
26. Brunner EJ, Hemingway H, Walker BR et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: Nested case-control study. Circulation 106(21), 2659-2665 (2002
27. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549), 2166-2170 (2001
28. Anagnostis P, Katsiki N, Adamidou F et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors. Novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism doi:10.1016/j. metabol.2012.05.002 (2012) (Epub ahead of print
29. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J. Clin. Endocrinol. Metab. 94(8), 2692-2701 (2009
30. Tamashiro KL. Metabolic syndrome: Links to social stress and socioeconomic status. Ann. NY Acad. Sci. 1231, 46-55 (2011
31. Gangwisch JE. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes. Rev. 10(SUPPL2), 37-45 (2009
32. Maury E, Ramsey KM, Bass J. Circadian rhythms and metabolic syndrome: From experimental genetics to human disease. Circ. Res. 106(3), 447-462 (2010
33. Chaput JP, Tremblay A. Does short sleep duration favor abdominal adiposity in childreñInt. J. Pediatr. Obes. 2(3), 188-191 (2007
34. Tombran-Tink J, Chader GG, Johnson LV. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 53(3), 411-414 (1991
35. Crowe S, Wu LE, Economou C et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab. 10(1), 40-47 (2009
36. Famulla S, Lamers D, Hartwig S et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int. J. Obes. (Lond.) 35(6), 762-772 (2011
37. Banumathi E, Sheikpranbabu S, Haribalaganesh R, Gurunathan S. PEDF prevents reactive oxygen species generation and retinal endothelial cell damage at high glucose levels. Exp. Eye Res. 90(1), 89-96 (2010
38. Zhang SX, Wang JJ, Dashti A et al. Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein. J. Mol. Endocrinol. 41(3), 135-143 (2008
39. Umei H, Yamagishi SI, Imaizumi T. Positive association of serum levels of pigment epithelium-derived factor with highsensitivity C-reactive protein in apparently healthy unmedicated subjects. J. Int. Med. Res. 38(2), 443-448 (2010
40. Dawson DW, Volpert OV, Gillis P et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 285(5425), 245-248 (1999
41. Chen C, Tso AW, Law LS et al. Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men. A 10-year prospective study. J. Clin. Endocrinol. Metab. 95(11), 5074-5081 (2010
42. Stejskal D, Karpisek M, Svestak M, Hejduk P, Sporova L, Kotolova H. Pigment epitheliumderived factor as a new marker of metabolic syndrome in Caucasian population. J. Clin. Lab. Anal. 24(1), 17-19 (2010
43. Yamagishi S, Adachi H, Abe A et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J. Clin. Endocrinol. Metab. 91(6), 2447-2450 (2006
44. Gattu AK, Birkenfeld AL, Jornayvaz F et al. Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients. Acta Diabetol. doi:10.1007/s00592-012-0397-y (2012) (Epub ahead of print
45. Notari L, Baladron V, Aroca-Aguilar JD et al. Identification of a lipase-linked cell membrane receptor for pigment epitheliumderived factor. J. Biol. Chem. 281(49), 38022-38037 (2006
46. Notari L, Arakaki N, Mueller D, Meier S, Amaral J, Becerra SP. Pigment epitheliumderived factor binds to cell-surface F1-ATP synthase. FEBS J. 277(9), 2192-2205 (2010
47. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type 2 diabetes. Nature 436(7049), 356-362 (2005
48. Abel ED, Peroni O, Kim JK et al. Adiposeselective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409(6821), 729-733 (2001
49. Graham TE, Yang Q, Bluher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354(24), 2552-2563 (2006
50. Gavi S, Qurashi S, Melendez MM, Mynarcik DC, McNurlan MA, Gelato MC. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and Type 2 diabetes: Response to Cho et al. Diabetes Care 30(3), e7; author reply e8 (2007
51. Cho YM, Youn BS, Lee H et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and Type 2 diabetes. Diabetes Care 29(11), 2457-2461 (2006
52. Gavi S, Stuart LM, Kelly P et al. Retinolbinding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without Type 2 diabetes. J. Clin. Endocrinol. Metab. 92(5), 1886-1890 (2007
53. Jia W, Wu H, Bao Y et al. Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without Type 2 diabetes. J. Clin. Endocrinol. Metab. 92(8), 3224-3229 (2007
54. Lee JW, Im JA, Lee HR, Shim JY, Youn BS, Lee DC. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity (Silver Spring) 15(9), 2225-2232 (2007
55. Kelly KR, Kashyap SR, O'Leary VB, Major J, Schauer PR, Kirwan JP. Retinol-binding protein 4 (RBP4) protein expression is increased in omental adipose tissue of severely obese patients. Obesity (Silver Spring) 18(4), 663-666 (2010
56. Kloting N, Graham TE, Berndt J et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-Abdominal fat mass. Cell Metab. 6(1), 79-87 (2007
57. Janke J, Engeli S, Boschmann M et al. Retinol-binding protein 4 in human obesity. Diabetes 55(10), 2805-2810 (2006
58. Lee JW, Lee HR, Shim JY, Im JA, Lee DC. Abdominal visceral fat reduction is associated with favorable changes of serum retinol binding protein-4 in nondiabetic subjects. Endocr. J. 55(5), 811-818 (2008
59. Vitkova M, Klimcakova E, Kovacikova M et al. Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during calorie restriction in obese subjects but are not related to diet-Induced changes in insulin sensitivity. J. Clin. Endocrinol. Metab. 92(6), 2330-2335 (2007
60. Nair AK, Sugunan D, Kumar H, Anilkumar G. Case-control analysis of SNPs in GLUT4, RBP4 and STRA6: Association of SNPs in STRA6 with Type 2 diabetes in a South Indian population. Plos One 5(7), e11444 (2010
61. Makino S, Fujiwara M, Suzukawa K et al. Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. Horm. Metab. Res. 41(3), 221-226 (2009
62. Lim S, Yoon JW, Choi SH et al. Combined impact of adiponectin and retinol-binding protein 4 on metabolic syndrome in elderly people. The Korean Longitudinal Study on Health and Aging. Obesity (Silver Spring) 18(4), 826-832 (2010
63. Wu Y, Li H, Loos RJ et al. RBP4 variants are significantly associated with plasma RBP4 levels and hypertriglyceridemia risk in Chinese Hans. J. Lipid Res. 50(7), 1479-1486 (2009
64. Bobbert T, Raila J, Schwarz F et al. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis 213(2), 549-551 (2010
65. Sasaki M, Otani T, Kawakami M, Ishikawa SE. Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction. Metabolism 59(4), 527-532 (2010
66. Ingelsson E, Sundstrom J, Melhus H et al. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis 206(1), 239-244 (2009
67. Mallat Z, Simon T, Benessiano J et al. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J. Clin. Endocrinol. Metab. 94(1), 255-260 (2009
68. Santoro N, Perrone L, Cirillo G et al. Variations of retinol binding protein 4 levels are not associated with changes in insulin resistance during puberty. J. Endocrinol. Invest. 32(5), 411-414 (2009
69. Aeberli I, Biebinger R, Lehmann R, L'allemand D, Spinas GA, Zimmermann MB. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J. Clin. Endocrinol. Metab. 92(11), 4359-4365 (2007
70. Von Eynatten M, Lepper PM, Liu D et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with Type 2 diabetes or coronary artery disease. Diabetologia 50(9), 1930-1937 (2007
71. Chavez AO, Coletta DK, Kamath S et al. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am. J. Physiol. Endocrinol. Metab. 296(4), E758-E764 (2009
72. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27(9), 3417-3428 (2007
73. Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282(37), 26687-26695 (2007
74. Yie J, Hecht R, Patel J et al. FGF21 N- And C-Termini play different roles in receptor interaction and activation. FEBS Lett. 583(1), 19-24 (2009
75. Kharitonenkov A, Dunbar JD, Bina HA et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215(1), 1-7 (2008
76. Sarruf DA, Thaler JP, Morton GJ et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59(7), 1817-1824 (2010
77. Galman C, Lundasen T, Kharitonenkov A et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8(2), 169-174 (2008
78. Inagaki T, Dutchak P, Zhao G et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5(6), 415-425 (2007
79. Sanchez J, Palou A, Pico C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: Striking effects on fibroblast growth factor-21 induction. Endocrinology 150(12), 5341-5350 (2009
80. Domouzoglou EM, Maratos-Flier E. Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. Am. J. Clin. Nutr. 93(4), 901S-905S (2011
81. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257(1), 79-83 (1999
82. Tschritter O, Fritsche A, Thamer C et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52(2), 239-243 (2003
83. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and Type 2 diabetes. Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86(5), 1930-1935 (2001
84. Daimon M, Oizumi T, Saitoh T et al. Decreased serum levels of adiponectin are a risk factor for the progression to Type 2 diabetes in the Japanese population: The Funagata study. Diabetes Care 26(7), 2015-2020 (2003
85. Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of Type 2 diabetes in the Pima Indian population. Lancet 360(9326), 57-58 (2002
86. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against Type 2 diabetes mellitus. Lancet 361(9353), 226-228 (2003
87. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of Type 2 diabetes in Asian indians. Diabetes Care 26(12), 3226-3229 (2003
88. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108(12), 1875-1881 (2001
89. Ouchi N, Kihara S, Arita Y et al. Adipocytederived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation 103(8), 1057-1063 (2001
90. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7(8), 941-946 (2001
91. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-Acid oxidation by activating AMP activated protein kinase. Nat. Med. 8(11), 1288-1295 (2002
92. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-Activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52(6), 1355-1363 (2003
93. Tsuchida A, Yamauchi T, Takekawa S et al. Peroxisome proliferator- Activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54(12), 3358-3370 (2005
94. Nawrocki AR, Rajala MW, Tomas E et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferatoractivated receptor gamma agonists. J. Biol. Chem. 281(5), 2654-2660 (2006
95. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(6941), 762-769 (2003
96. Kubota N, Yano W, Kubota T et al. Adiponectin stimulates AMP-Activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6(1), 55-68 (2007
97. Lamers D, Famulla S, Wronkowitz N et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60(7), 1917-1925 (2011
98. Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Curr. Opin. Lipidol. 22(3), 210-215 (2011
99. Santoro N, Cirillo G, Amato A et al. Insulin gene variable number of tandem repeats (INS VNTR) genotype and metabolic syndrome in childhood obesity. J. Clin. Endocrinol. Metab. 91(11), 4641-4644 (2006